Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.20.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Net loss attributable to Sonnet BioTherapeutics Holdings, Inc. $ (1,921,569) $ (1,873,072)
Foreign currency translation gain / (loss) (81,069) 37,832
Total other comprehensive income (81,069) 37,832
Comprehensive loss $ (2,002,638) $ (1,835,240)